1. Immunology and Inflammation

Discovery of surrogate agonists for visceral fat Treg cells that modulate metabolic indices in vivo

  1. Ricardo A Fernandes
  2. Chaoran Li
  3. Gang Wang
  4. Xinbo Yang
  5. Christina S Savvides
  6. Caleb R Glassman
  7. Shen Dong
  8. Eric Luxenberg
  9. Leah V Sibener
  10. Michael E Birnbaum
  11. Christophe Benoist
  12. Diane Mathis  Is a corresponding author
  13. K Christopher Garcia  Is a corresponding author
  1. Stanford University School of Medicine, United States
  2. Harvard Medical School, United States
  3. Stanford University School of Engineering, United States
  4. Howard Hughes Medical Institute, Stanford University School of Medicine, United States
https://doi.org/10.7554/eLife.58463
Share this article
Cite this article
  1. Ricardo A Fernandes
  2. Chaoran Li
  3. Gang Wang
  4. Xinbo Yang
  5. Christina S Savvides
  6. Caleb R Glassman
  7. Shen Dong
  8. Eric Luxenberg
  9. Leah V Sibener
  10. Michael E Birnbaum
  11. Christophe Benoist
  12. Diane Mathis
  13. K Christopher Garcia
(2020)
Discovery of surrogate agonists for visceral fat Treg cells that modulate metabolic indices in vivo
eLife 9:e58463.
https://doi.org/10.7554/eLife.58463
  2. Download BibTeX
  3. Download .RIS

Abstract

T regulatory (Treg) cells play vital roles in modulating immunity and tissue homeostasis. Their actions depend on TCR recognition of peptide-MHC molecules; yet the degree of peptide specificity of Treg-cell function, and whether Treg ligands can be used to manipulate Treg cell biology are unknown. Here, we developed an Ab-peptide library that enabled unbiased screening of peptides recognized by a bona fide murine Treg cell clone isolated from the visceral adipose tissue (VAT), and identified surrogate agonist peptides, with differing affinities and signaling potencies. The VAT-Treg cells expanded in vivo by one of the surrogate agonists preserved the typical VAT-Treg transcriptional programs. Immunization with this surrogate, especially when coupled with blockade of TNFa signaling, expanded VAT-Treg cells, resulting in protection from inflammation and improved metabolic indices, including promotion of insulin sensitivity. These studies suggest that antigen-specific targeting of VAT-localized Treg cells could eventually be a strategy for improving metabolic disease.

Data availability

Sequencing data for the peptide-Ab yeast library screening and RNA-seq data for VAT-Treg cells have been deposited in GEO under accession codes GSE151070 and GSE150173. Custom Perl scripts for the processing of the deep sequencing data for the peptide-Ab is available from: https://github.com/jlmendozabio/NGSpeptideprepandpred.

The following data sets were generated

Article and author information

Author details

  1. Ricardo A Fernandes

    Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, United States
    Competing interests
    The authors declare that no competing interests exist.

  2. Chaoran Li

    Department of Immunology, Harvard Medical School, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.

  3. Gang Wang

    Department of Immunology, Harvard Medical School, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.

  4. Xinbo Yang

    Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, United States
    Competing interests
    The authors declare that no competing interests exist.

  5. Christina S Savvides

    Biology, Stanford University School of Medicine, Stanford, United States
    Competing interests
    The authors declare that no competing interests exist.

  6. Caleb R Glassman

    Molecular & Cellular Physiology and Structural Biology, Stanford University School of Medicine, Stanford, United States
    Competing interests
    The authors declare that no competing interests exist.

  7. Shen Dong

    Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, United States
    Competing interests
    The authors declare that no competing interests exist.

  8. Eric Luxenberg

    Department of Electrical Engineering, Stanford University School of Engineering, Stanford, United States
    Competing interests
    The authors declare that no competing interests exist.

  9. Leah V Sibener

    Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, United States
    Competing interests
    The authors declare that no competing interests exist.

  10. Michael E Birnbaum

    Molecular & Cellular Physiology and Structural Biology, Stanford University School of Medicine, Stanford, United States
    Competing interests
    The authors declare that no competing interests exist.

  11. Christophe Benoist

    Department of Immunology, Harvard Medical School, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.

  12. Diane Mathis

    Department of Immunology, Harvard Medical School, Boston, United States
    For correspondence
    diane_mathis@hms.harvard.edu
    Competing interests
    The authors declare that no competing interests exist.

  13. K Christopher Garcia

    Department of Molecular and Cellular Physiology, Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, United States
    For correspondence
    kcgarcia@stanford.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9273-0278

Funding

Wellcome (WT101609MA)

  • Ricardo A Fernandes

NIH Office of the Director (5R01AI103867)

  • K Christopher Garcia

Howard Hughes Medical Institute (HHMI)

  • K Christopher Garcia

G Harold and Leila Y. Mathers Foundation

  • K Christopher Garcia

NIH Clinical Center (2R01 DK092541)

  • Diane Mathis

JPB Foundation

  • Diane Mathis

NIH Office of the Director (UC4DK116264)

  • K Christopher Garcia

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health and every effort was made to minimize suffering. All experiments were performed following animal protocols approved by the HMS Institutional Animal Use and Care Committee (protocol IS00001257).

Copyright

© 2020, Fernandes et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,618
    views
  • 431
    downloads
  • 23
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Ricardo A Fernandes
  2. Chaoran Li
  3. Gang Wang
  4. Xinbo Yang
  5. Christina S Savvides
  6. Caleb R Glassman
  7. Shen Dong
  8. Eric Luxenberg
  9. Leah V Sibener
  10. Michael E Birnbaum
  11. Christophe Benoist
  12. Diane Mathis
  13. K Christopher Garcia
(2020)
Discovery of surrogate agonists for visceral fat Treg cells that modulate metabolic indices in vivo
eLife 9:e58463.
https://doi.org/10.7554/eLife.58463

Share this article

https://doi.org/10.7554/eLife.58463

Categories and tags

Research organism

Further reading

    1. Cell Biology
    2. Immunology and Inflammation

    UFMTrack, an Under-Flow Migration Tracker enabling analysis of the entire multi-step immune cell extravasation cascade across the blood-brain barrier in microfluidic devices

    Mykhailo Vladymyrov, Luca Marchetti ... Britta Engelhardt
    Tools and Resources

    The endothelial blood-brain barrier (BBB) strictly controls immune cell trafficking into the central nervous system (CNS). In neuroinflammatory diseases such as multiple sclerosis, this tight control is, however, disturbed, leading to immune cell infiltration into the CNS. The development of in vitro models of the BBB combined with microfluidic devices has advanced our understanding of the cellular and molecular mechanisms mediating the multistep T-cell extravasation across the BBB. A major bottleneck of these in vitro studies is the absence of a robust and automated pipeline suitable for analyzing and quantifying the sequential interaction steps of different immune cell subsets with the BBB under physiological flow in vitro. Here, we present the under-flow migration tracker (UFMTrack) framework for studying immune cell interactions with endothelial monolayers under physiological flow. We then showcase a pipeline built based on it to study the entire multistep extravasation cascade of immune cells across brain microvascular endothelial cells under physiological flow in vitro. UFMTrack achieves 90% track reconstruction efficiency and allows for scaling due to the reduction of the analysis cost and by eliminating experimenter bias. This allowed for an in-depth analysis of all behavioral regimes involved in the multistep immune cell extravasation cascade. The study summarizes how UFMTrack can be employed to delineate the interactions of CD4+ and CD8+ T cells with the BBB under physiological flow. We also demonstrate its applicability to the other BBB models, showcasing broader applicability of the developed framework to a range of immune cell-endothelial monolayer interaction studies. The UFMTrack framework along with the generated datasets is publicly available in the corresponding repositories.

    1. Immunology and Inflammation

    Coevolutionary interplay: Helminths-trained immunity and its impact on the rise of inflammatory diseases

    Eugenio Antonio Carrera Silva, Juliana Puyssegur, Andrea Emilse Errasti
    Review Article

    The gut biome, a complex ecosystem of micro- and macro-organisms, plays a crucial role in human health. A disruption in this evolutive balance, particularly during early life, can lead to immune dysregulation and inflammatory disorders. ‘Biome repletion’ has emerged as a potential therapeutic approach, introducing live microbes or helminth-derived products to restore immune balance. While helminth therapy has shown some promise, significant challenges remain in optimizing clinical trials. Factors such as patient genetics, disease status, helminth species, and the optimal timing and dosage of their products or metabolites must be carefully considered to train the immune system effectively. We aim to discuss how helminths and their products induce trained immunity as prospective to treat inflammatory and autoimmune diseases. The molecular repertoire of helminth excretory/secretory products (ESPs), which includes proteins, peptides, lipids, and RNA-carrying extracellular vesicles (EVs), underscores their potential to modulate innate immune cells and hematopoietic stem cell precursors. Mimicking natural delivery mechanisms like synthetic exosomes could revolutionize EV-based therapies and optimizing production and delivery of ESP will be crucial for their translation into clinical applications. By deciphering and harnessing helminth-derived products’ diverse modes of action, we can unleash their full therapeutic potential and pave the way for innovative treatments.

    1. Immunology and Inflammation

    The extra-islet pancreas supports autoimmunity in human type 1 diabetes

    Graham L Barlow, Christian M Schürch ... Paul L Bollyky
    Research Article

    In autoimmune type 1 diabetes (T1D), immune cells infiltrate and destroy the islets of Langerhans — islands of endocrine tissue dispersed throughout the pancreas. However, the contribution of cellular programs outside islets to insulitis is unclear. Here, using CO-Detection by indEXing (CODEX) tissue imaging and cadaveric pancreas samples, we simultaneously examine islet and extra-islet inflammation in human T1D. We identify four sub-states of inflamed islets characterized by the activation profiles of CD8+T cells enriched in islets relative to the surrounding tissue. We further find that the extra-islet space of lobules with extensive islet-infiltration differs from the extra-islet space of less infiltrated areas within the same tissue section. Finally, we identify lymphoid structures away from islets enriched in CD45RA+ T cells — a population also enriched in one of the inflamed islet sub-states. Together, these data help define the coordination between islets and the extra-islet pancreas in the pathogenesis of human T1D.